← All trials
NCT06999187
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 3, 2025
- Primary completion
- Jul 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- May 31, 2025
- Last posted
- Aug 19, 2025
- Enrollment
- 96
- Arms / groups
- 8 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Stomach Neoplasms
- Endometrial Neoplasms
- Prostatic Neoplasms, Castration-Resistant
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.